Amarin Corporation

Amarin Corporation EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Amarin Corporation (AMRN) as of Nov 19, 2026 is -2.08 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -13.39 % — a change of -84.48% (higher).

EBIT/Assets

-2.08 %

YoY

-84.48%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Amarin Corporation is 2025 -2.08 % . Operating Income to Assets Ratio (EBIT/Assets) of Amarin Corporation was 2024 -13.39 % . It decreases by -84.48% higher compared to the previous year.

The Amarin Corporation EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-28.06 USD
Jan 1, 2019
-2.75 USD
Jan 1, 2020
-2.03 USD
Jan 1, 2021
0.98 USD
Jan 1, 2022
-11.95 USD
Jan 1, 2023
-6.81 USD
Jan 1, 2024
-13.39 USD
Jan 1, 2025
-2.08 USD
The Amarin Corporation EBIT/Assets history
YEAREBIT/AssetsYoY
-2.08 %-84.48%
-13.39 %+96.76%
-6.81 %-43.02%
-11.95 %-1,314.99%
0.98 %-148.33%
-2.03 %-26.07%
-2.75 %-90.19%
-28.06 %-0.47%
-28.19 %-28.26%
-39.30 %-30.60%
-56.62 %+0.97%
-56.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Operating Income to Assets Ratio (EBIT/Assets) of Amarin Corporation is -2.08 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Amarin Corporation changed from -13.39 % to -2.08 %, representing a -84.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Amarin Corporation

All Key Metrics — Amarin Corporation